ETHZilla Corporation Common Stock
ETHZilla Corporation Common Stock
Your view on ATNF
Overview
What the company does, where it operates, and who runs it.
About ETHZilla Corporation Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lloyd Blair Jordan
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lloyd Blair Jordan
- Headquarters
- US
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ETHZilla Corporation Common Stock, and the rating behind it. ATNF last traded at $7.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ETHZilla Corporation Common Stock. Starting points for ETHZilla Corporation Common Stock: EPS -$2640.30, beta 0.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ETHZilla Corporation Common Stock. ETHZilla Corporation Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ETHZilla Corporation Common Stock. Trailing twelve-month EPS for ETHZilla Corporation Common Stock stands at -$2640.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ETHZilla Corporation Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ETHZilla Corporation Common Stock valued side by side against its closest peers. ETHZilla Corporation Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ETHZilla Corporation Common Stock, and how their positions are changing. At a $1.08B market value, institutional positions materially move ETHZilla Corporation Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ETHZilla Corporation Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ETHZilla Corporation Common Stock. ETHZilla Corporation Common Stock is a $1.08B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ETHZilla Corporation Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ETHZilla Corporation Common Stock. Coverage tracks ETHZilla Corporation Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.